AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05965739 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BrainHQ/Active Comparator Activity
Description: BrainHQ platform provides a set of cognitive activities, like puzzles and games, that are cognitively stimulating and actively engage participants but do not continuously and adaptively challenge them. These activities are designed to be a face-valid, active comparison approach to cognitive therapy, thus participants are blinded, attention time is matched, and overall user experience is identical to the active arms.
Study NCT05965739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BrainHQ
Description: BrainHQ is an online cognitive training program, and has been used to improve cognitive function among persons with cognitive impairment based on principles of neuroplasticity.
Study NCT05965739 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: BrainHQ
Description: BrainHQ is an online cognitive training program, and has been used to improve cognitive function among persons with cognitive impairment based on principles of neuroplasticity.
Study NCT05965739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PASC CoRE
Description: PASC CoRE is a manualized, adaptable cognitive rehabilitation intervention adapted from Goal Management Training and other evidence based programs that improve attention and executive functions, among other cognitive domains.
Study NCT05965739 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS-active
Description: Transcranial direct current stimulation (tDCS) will use a device specifically for home-based use. This device delivers a weak electrical current of 2.0 mA passed through two electrodes placed on the scalp to target the dorsolateral prefrontal cortex region of the brain. The electrodes are single-use for each session and can be attached to a headset by snapping into place.~The device has a user-friendly interface and a large-button keypad, making it is easy to use at home.
Study NCT05965739 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: tDCS-sham
Description: tDCS devices used in the sham arm will be pre-programmed to deliver the same ramp up/down at the beginning/end of the 30-minute period as the active arm, except with no current otherwise delivered during the session.
Study NCT05268419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethanol
Description: Inhalation of 35%-ethanol spray
Study NCT05268419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Water Distilled
Description: Inhalation of water distilled spray
Study NCT05312476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets
Description: 1. Dose escalation studies:3 dose groups in total: expect 3-6 cases in each group, and dose set at 1×106/kg，3×106/kg，6×106/kg.~2. Dose extension study:3 cases (1 dose group).
Study NCT05017649 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sample
Description: Blood sampling.
Study NCT05017649 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sampling.
Study NCT06555497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical 1% methotrexate gel
Description: topical 1% methotrexate gel
Study NCT06555497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clobetasol propionate 0.05% ointment
Description: clobetasol propionate 0.05% ointment
Study NCT05491109 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Venous Assistance and Contracture Management System (VACOM)
Description: Mimic therapist-assisted on bed passive ankle exercises to preclude the development of ankle joint contracture and facilitate venous flow in lower extremities to reduce DVT risk. Using soft pneumatic extension actuators, which is capable of providing robot-assisted ankle exercises, specifically dorsiflexion-plantarflexion and inversion-eversion movements. Through these natural movements to improve blood flow and venous return and maintain ankle joint flexibility. Furthermore, it can facilitate and stimulate the neurologic recovery in walking by early mobilization.
Study NCT05491109 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venous Assistance and Contracture Management System (VACOM)
Description: Mimic therapist-assisted on bed passive ankle exercises to preclude the development of ankle joint contracture and facilitate venous flow in lower extremities to reduce DVT risk. Using soft pneumatic extension actuators, which is capable of providing robot-assisted ankle exercises, specifically dorsiflexion-plantarflexion and inversion-eversion movements. Through these natural movements to improve blood flow and venous return and maintain ankle joint flexibility. Furthermore, it can facilitate and stimulate the neurologic recovery in walking by early mobilization.
Study NCT05856227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftobiprole medocaril
Description: Ceftobiprole medocaril: 7.5 mg/kg every 12 hours to 15 mg/kg every 8 hours, administered IV as a 2-hour infusion.
Study NCT04991324 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 24,000 IU cholecalciferol
Study NCT04991324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 24,000 IU cholecalciferol
Study NCT06425133 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: Blood sample for plasma collection, Blood sample for ctDNA (circulating tumoral DNA) collection
Study NCT06425133 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample for plasma collection, Blood sample for ctDNA (circulating tumoral DNA) collection
Study NCT06425133 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality of life questionnaires
Description: EORTC QLQ-C30 questionnaire (Quality of life questionnaire Cancer 30) CR29 questionnaire (Colo-rectal cancer 29) EQ-5D5L questionnaire (EuroQol-5 Dimensions, 5 levels): repeated measures at baseline, M2, M4, M6, M8, M10, M12 and during the end of treatment visit and during the follow-up
Study NCT06425133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaires
Description: EORTC QLQ-C30 questionnaire (Quality of life questionnaire Cancer 30) CR29 questionnaire (Colo-rectal cancer 29) EQ-5D5L questionnaire (EuroQol-5 Dimensions, 5 levels): repeated measures at baseline, M2, M4, M6, M8, M10, M12 and during the end of treatment visit and during the follow-up
Study NCT06378788 — intervention group
Intervention type: OTHER
Intervention: Demographic information form
Description: aims to collect basic demographic data( Age reported by years , weight and height will be combined to report Body Mass index (BMİ) in kg/m2, Smoking habit reported as smoker or non-smoker , Level of Education reported as illiterate, literate, Primary school, Middle school, High school, University or Post-graduate, Profession type, Significant medical records and Medications.
Study NCT06378788 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: widespread pain index (WPI)
Description: The Widespread Pain Index is a 19-point checklist that assesses the presence of pain or tenderness (within the prior seven days) in 19 specific areas of the body; each affected area receives one point. The 19 regions on the WPI include the following:~Right and left jaw, Right and left shoulder girdle, Right and left upper arm, Right and left lower arm, Right and left hip/buttock Right and left upper leg Right and left lower leg Upper and lower back Neck Chest Abdomen A fibromyalgia diagnosis is confirmed if a WPI is ≥7 with an SS scale ≥5 OR a WPI range between 4-6 with an SS scale ≥ 9.
Study NCT06378788 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: symptom severity scale (SSS)
Description: SS scale score: Fatigue, waking unrefreshed, and cognitive symptoms. For each of the three symptoms above, indicate the severity level over the past week utilizing the following scale: 0 no problem; 1 slight or mild problems, generally mild or intermittent; 2 moderate, considerable problems, often present and/or at a moderate level; 3 severe: pervasive, continuous, life-disturbing problems. Considering somatic symptoms in general, indicate whether the patient has: 0 for no symptoms, 1 for a few symptoms, 2 for a moderate number of symptoms, and 3 for many symptoms. The SS scale score sums the severity of the 3 symptoms (fatigue, waking unrefreshed, cognitive symptoms) plus the severity) of general somatic symptoms. The final score is between 0 and 12.
Study NCT06378788 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fibromyalgia Impact Questionnaire (FIQ)
Description: The FIQ is an assessment and evaluation instrument developed to measure fibromyalgia (FM) patient status, progress and outcomes. The FIQ is composed of 10 items. The first item contains 11 questions related to physical functioning - each question is rated on a 4 point Likert type scale. Items 2 and 3 ask the patient to mark the number of days they felt well and the number of days they were unable to work (including housework) because of fibromyalgia symptoms. Items 4 through 10 are horizontal linear scales marked in 10 increments on which the patient rates work difficulty, pain, fatigue, morning tiredness, stiffness, anxiety and depression.
Study NCT06378788 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tender Point examination
Description: Tender points are specific sites on the body that cause pain when pressed.. There are 9 pairs of tender points. Each pair has one point on each side of the body, for a total of 18 points.Prior to 2010, the diagnosis of fibromyalgia required at least 11 painful point of 18 but now tender points are no longer used as a diagnostic tool. The score will be reported as the number of tender points found with palpation.
Study NCT06378788 — intervention group
Intervention type: OTHER
Intervention: Muscle Architecture visualized with ultrasound
Description: The three head of Quadratus femoris ( Vastus lateralis, Vastus Medialis and Rectus Femoris), Tibialis Anterior, the two heads of Gastrocnemius ( vastus Lateralis and vastus Medialis) ultrasonography will be performed to evaluate muscle thickness, pennation angle and fascicle length.
Study NCT06378788 — intervention group
Intervention type: OTHER
Intervention: Sarcopenia assessed by measuring isometric strengths of different parts of the body
Description: Cervical Flexion (CF), Cervical Extension (CE), Right and Left Cervical Lateral Flexion (CLF R/L), Truncal flexion (TF), Truncal extension (TE), Shoulder flexion (SF), Shoulder extension (SE), Shoulder abduction (SAB), Shoulder internal rotation (SIR) and Shoulder external rotation (SER), Hip flexion (HF), Hip extension (HE), hip abduction (HAB), hip internal rotation (HIR), hip external rotation (HER), knee extension (KE), Knee Flexion (KF), Ankle Dorsiflexion (ADF) and Ankle Plantar flexion (APF) muscle strengths will be evaluated with hand held dynamometer
Study NCT06378788 — intervention group
Intervention type: OTHER
Intervention: Timed Up & Go (TUG)
Description: The test will be used by investigators as a simple evaluative test used to measure participants functional mobility.
Study NCT04680052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafasitamab
Description: tafasitamab will be administered IV for 12 cycles
Study NCT04680052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Rituximab will be administered IV on cycles 1 - 5
Study NCT04680052 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rituximab
Description: Rituximab will be administered IV on cycles 1 - 5
Study NCT04680052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Lenalidomide will be administered PO for 12 cycles
Study NCT04680052 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lenalidomide
Description: Lenalidomide will be administered PO for 12 cycles
Study NCT04680052 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo will be administered IV for 12 cycles
Study NCT06425133 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Fresh tumor biopsy at baseline and week 8
Study NCT06425133 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Fresh tumor biopsy at baseline and week 8
Study NCT06425133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: For the first cycle: Regorafenib will be administered according to the REDOS schedule: week 1: 80 mg regorafenib daily week 2: 120 mg regorafenib daily week 3: 160 mg regorafenib daily week 4 : OFF. For the following cycles: regorafenib will be administered at 160mg in the absence of significant toxicity during cycle 1 or at a 80/120mg daily dose according to toxicity observed with the last dose used in the first cycle.
Study NCT06124404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate
Description: After a loading dose of 0.08mg/kg, a maintaining dose of 0.2mg/kg/h is given
Study NCT06124404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate
Description: After a loading dose of 0.08mg/kg, a maintaining dose of 0.4mg/kg/h is given
Study NCT06129955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pucotenlimab Combined With Lenvatinib
Description: Patients treated by Pucotenlimab combined with Lenvatinib for 3 months before surgery
Study NCT06425133 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Regorafenib + metronomic chemotherapy
Description: • Regorafenib will be administered 3 weeks out of 4 (1 cycle corresponding to 4 weeks) until progression or unacceptable toxicity.~For the first cycle: Regorafenib will be administered according to the REDOS schedule: week 1: 80 mg regorafenib daily week 2: 120 mg regorafenib daily week 3: 160 mg regorafenib daily week 4 : OFF. For the following cycles: regorafenib will be administered at 160mg in the absence of significant toxicity during cycle 1 or at a 80/120mg daily dose according to toxicity observed with the last dose used in the first cycle.~* Metronomic chemotherapy will be administrated as following:Cyclophosphamide: 50 mg per os, daily, for 6 months,Capecitabine: 625mg/m²/orally twice daily, for 6 months.~* Low-dose Aspirin: 75 mg orally, daily, until progression.
Study NCT05249543 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified protocol
Description: Transdiagnostic cognitive-behavioral therapy
Study NCT05249543 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diagnosis-specific cognitive-behavioral therapy
Description: Diagnosis-specific cognitive-behavioral therapy
Study NCT05176067 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic Three-dimensional Radiotherapy
Description: Drug Therapy Combined With Thoracic Three-dimensional Radiotherapy
Study NCT05035173 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survivorship Clinic Assessments
Description: Patients will visit in person the Survivorship Clinic at the baseline and end of the study (12-month) at the ORCHID center in the Cork University Hospital (Cork, Ireland).~During these visits, baseline and end of the study assessments will be made. Patients will receive routine standard information, a care plan and resources about survivorship at the baseline visit.
Study NCT05035173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survivorship Clinic Assessments
Description: Patients will visit in person the Survivorship Clinic at the baseline and end of the study (12-month) at the ORCHID center in the Cork University Hospital (Cork, Ireland).~During these visits, baseline and end of the study assessments will be made. Patients will receive routine standard information, a care plan and resources about survivorship at the baseline visit.
Study NCT05035173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survivorship Clinic Nurse Resource
Description: Patients will receive a Survivorship Personal Treatment Plan by the nurse from the Women's Health Initiative Survivorship Clinic according to the results from the baseline ePROs. In addition to that, each 2 months for a period of 12 months, the patient will be answering ePROs. The nurse will undertake an intervention when needed based as per the Trigger system (developed form ePROs responses) or clinical judgement.~- ePRO Symptom Survey Instrument (nurse questions): A core list of symptoms/adverse events that are identified including gastrointestinal, attention/memory, pain, fatigue and insomnia, mood-emotional distress/depression, anxiety, fear of cancer recurrence, gynaecological, urinary, sexual issues, hot flashes.
Study NCT05035173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survivorship Clinic Dietitian Resource
Description: Patients will receive Diet Education and Personalised Nutrition Counselling by the dietitian from the Women's Health Initiative Survivorship Clinic at the baseline. In addition to that, each 2 months for a period of 12 months, the patient will be answering ePROs. The dietitian will undertake an intervention when needed as per the Trigger system (developed form ePROs responses) or clinical judgement.~- ePRO Symptom Survey Instrument (diet questions): nutritional risk (lack of appetite; worry regarding weight loss; worry regarding weight gain), weight, and exercise.
Study NCT06090799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-3032
Description: Single dose at varying dosage levels depending on treatment assignment
Study NCT06090799 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHR-3032 Placebo
Description: Single dose at varying dosage levels depending on treatment assignment
Study NCT05573308 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clear Aligners with Dental Monitoring
Description: Dental Monitoring™ (DM ™). This digital technology software allows orthodontists to monitor patients remotely through continuous analytics using control vision technology, metaheuristics, and artificial intelligence.31 This app utilizes a patented artificial intelligence machine learning algorithm to calculate 3-dimensional (3D) tooth movements from intraoral photos and videos that patients capture using their smartphone cameras.
Study NCT05573308 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear Aligners
Description: Removabale orthodontics appliances
Study NCT06036368 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peroneal electrical transcutaneous neuromodulation (peroneal eTNM®)
Description: This is a non-invasive intervention, which utilizes direct trancutaneous, electrical stimulation of the peroneal nerve
Study NCT06241846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YL201 for Injection
Description: Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks on Day 1 or twice every 3 weeks on Day 1 and Day 8 during a 3-week (21-day) cycle.
Study NCT05660538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-548
Description: Tablets for oral administration.
Study NCT04463576 — intervention group
Intervention type: OTHER
Intervention: Discharge Prescription
Description: All hospital discharge prescriptions for patients aged 65 or over hospitalized or seen in consultation in the cardiology, internal medicine and neurology divisions of the Bordeaux and Rennes University Hospital and Georges Pompidou European Hospital will be recorded between June 1, 2018 and June 1, 2019.
Study NCT05733598 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP2
Description: Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation.
Study NCT05733598 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Anti-VEGF therapy.
Study NCT05733598 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Anti-PD-L1 monoclonal antibody.
Study NCT05092386 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational 13-valent Pneumococcal Polysaccharide Conjugate Vaccine
Description: The investigational vaccine was manufactured by Sinovac Research \& Development Co., Ltd. each for purified 13 serotypes of pneumococcal polysaccharide and diphtheria CRM197 in 0·5 mL of aluminum phosphate ,sodium chloride,polysorbate 80 and succinic acid per injection.
Study NCT05092386 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Control 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ( WALVAX PCV13)
Description: The control vaccine was manufactured by WALVAX Biotechnology Co., Ltd. each for purified 13 serotypes of pneumococcal polysaccharide and tetanus toxoid vector (TT) in 0·5 mL of aluminum phosphate ,disodium hydrogen phosphate and sodium dihydrogen phosphate per injection.
Study NCT05092386 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Control 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ( Pfizer PCV13)
Description: The control vaccine was manufactured by Pfizer. each for purified 13 serotypes of pneumococcal polysaccharide and tetanus toxoid vector (TT) in 0·5 mL of aluminum phosphate ,sodium chloride ,succinic acid ,polysorbate 80 and water for injection per injection.
Study NCT05802056 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given IP
Study NCT05802056 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT05802056 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood and tissue samples
Study NCT05802056 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT
Study NCT05802056 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Laparoscopy
Description: Undergo diagnostic laparoscopy
Study NCT05802056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT05802056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV